Which adults with metastatic or locally recurrent unresectable breast cancer are eligible for pertuzumab (Perjeta)?

Perjeta (pertuzumab), with trastuzumab and docetaxel, is indicated for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.